Shanghai, Hangzhou, February 28, 2022 — Hangzhou Sumgen Biotech Co., Ltd. ("Sumgen") and Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") have reached a strategic cooperation agreement to jointly develop a new generation of antibody-drug conjugates (ADCs).

On July 21, 2021, Shanghai Escugen Biotech Co., Ltd. announced that it has officially received the approval notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the clinical trial application (IND) of its recombinant humanized anti-Trop2 monoclonal antibody-SN38 conjugate (acceptance number CXSL2101069).